Premium
S‐ketamine and GABA‐A‐receptor interaction in humans: an exploratory study with I‐123‐iomazenil SPECT
Author(s) -
Heinzel Alexander,
Steinke Rainer,
Poeppel Thorsten Dirk,
Grosser Oliver,
Bogerts Bernhard,
Otto Hans,
Northoff Georg
Publication year - 2008
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.960
Subject(s) - ketamine , statistical parametric mapping , prefrontal cortex , placebo , nmda receptor , psychology , medicine , anesthesia , pharmacology , neuroscience , receptor , magnetic resonance imaging , pathology , radiology , cognition , alternative medicine
Objective We aimed to probe for regional cerebral effects of S‐ketamine on in vivo GABA‐A‐receptor binding in healthy human subjects. Methods We investigated I‐123‐iomazenil SPECT before, during and after administration of S‐ketamine in a blinded placebo‐controlled study design ( n = 12 in both groups). Analyses of SPECT were performed with voxel‐based statistical parametric mapping (SPM), and statistical comparisons were made between the groups. We also assessed biochemical and behavioural changes during S‐ketamine infusion. Results S‐ketamine induced positive and negative symptoms measured by the Brief Psychiatric Rating scale (BPRS). It increased the cortisol and prolactin levels. Image analysis revealed significantly decreased I‐123‐iomazenil binding in bilateral dorsomedial prefrontal cortex during S‐ketamine administration when compared to placebo. Conclusion Our study delivers preliminary evidence for an in vivo interaction of S‐ketamine with GABA‐A‐receptors in human dorsomedial prefrontal cortex. Copyright © 2008 John Wiley & Sons, Ltd.